Teriparatide and Abaloparatide Have a Similar Effect on Bone in Mice

Mikkel Bo Brent, Frederik Eriksen Stoltenborg, Annemarie Brüel, Jesper Skovhus Thomsen, Mikkel Bo Brent, Frederik Eriksen Stoltenborg, Annemarie Brüel, Jesper Skovhus Thomsen

Abstract

Three bone anabolic pharmaceuticals are currently approved for treatment of osteoporosis, teriparatide (PTH (1-34)), the parathyroid hormone-related protein analog abaloparatide (ABL), and romosozumab. The present study compared the effect of intermittent PTH (1-34) and ABL on bone tissue directly mole-to-mole in female mice. Forty-seven C57BL/6 mice were randomly allocated to the following groups: Baseline (n = 11), Control (Ctrl) (n = 12), PTH (n = 12), and ABL (n = 12). The mice were injected s.c. with PTH (100 µg/kg), ABL (96 µg/kg), or saline (Ctrl) five days a week for three weeks. To assess the effect of PTH and ABL, the hindlimb bones were analyzed with DXA, µCT, mechanical testing, dynamic bone histomorphometry, and histological quantification of bone cells. In addition, serum calcium concentration was determined. PTH and ABL significantly increased femoral areal bone mineral density (aBMD) (borderline significant p = 0.06 for PTH), femoral mid-diaphyseal bone strength, femoral metaphyseal and epiphyseal and vertebral bone volume fraction (BV/TV), connectivity density, volumetric bone mineral density (vBMD), and bone formation rate (BFR/BS) compared to Ctrl. In addition, ABL also significantly increased mid-diaphyseal cortical thickness and bone area compared to Ctrl. Neither PTH nor ABL significantly increased bone strength at the femoral neck. In conclusion, abaloparatide and PTH have similar bone anabolic properties when compared directly mole-to-mole in mice.

Keywords: PTH; abaloparatide; bone formation; bone strength; μCT.

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be constructed as a potential conflict of interest.

Copyright © 2021 Brent, Stoltenborg, Brüel and Thomsen.

Figures

Figure 1
Figure 1
Micro-computed tomography (μCT) scan of a mouse femur and vertebra L4. (A) The magenta area represents the analyzed volume of interest (VOI) of the distal femoral metaphysis and (B) the yellow area represents the VOI of the distal femoral epiphysis consisting of trabecular bone only. (C) The blue areas represent the VOI consisting of cortical bone only at the femoral mid-diaphysis. (D) The green area represents the VOI containing trabecular bone only at vertebra L4. Dimensions are not to scale.
Figure 2
Figure 2
(A) 3D reconstructions of 105-μm-thick representative frontal slices through the distal femoral metaphyseal and epiphyseal. (B, C) Bone volume fraction (BV/TV) at the distal femoral metaphysis and epiphysis determined by μCT. Data are presented as mean ± SD. *p < 0.05 vs. Ctrl.

References

    1. Compston JE, McClung MR, Leslie WD. Osteoporosis. Lancet (2019) 393:364–76. 10.1016/S0140-6736(18)32112-3
    1. Borgström F, Karlsson L, Ortsäter G, Norton N, Halbout P, Cooper C, et al. . Fragility fractures in Europe: burden, management and opportunities. Arch Osteoporos (2020) 15. 10.1007/s11657-020-0706-y
    1. Rachner TD, Khosla S, Hofbauer LC. Osteoporosis: Now and the future. Lancet (2011) 377:1276–87. 10.1016/S0140-6736(10)62349-5
    1. Khosla S, Hofbauer LC. Osteoporosis treatment: recent developments and ongoing challenges. Lancet Diabetes Endocrinol (2017) 5:898–907. 10.1016/S2213-8587(17)30188-2
    1. Brixen KT, Christensen PM, Ejersted C, Langdahl BL. Teriparatide (biosynthetic human parathyroid hormone 1-34): A new paradigm in the treatment of osteoporosis. Basic Clin Pharmacol Toxicol (2004) 94:260–70. 10.1111/j.1742-7843.2004.pto940602.x
    1. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, et al. . Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med (2001) 344:1434–41. 10.1056/NEJM200105103441904
    1. Jilka RL. Molecular and cellular mechanisms of the anabolic effect of intermittent PTH. Bone (2007) 40:1434–46. 10.1016/j.bone.2007.03.017
    1. Marcocci C, Cianferotti L, Cetani F. Bone disease in primary hyperparathyrodism. Ther Adv Musculoskelet Dis (2012) 4:357–68. 10.1177/1759720X12441869
    1. Cheloha RW, Gellman SH, Vilardaga JP, Gardella TJ. PTH receptor-1 signalling - Mechanistic insights and therapeutic prospects. Nat Rev Endocrinol (2015) 11:712–24. 10.1038/nrendo.2015.139
    1. Whitfield JF, Morley P, Willick GE. Parathyroid hormone, its fragments and their analogs for the treatment of osteoporosis. Treat Endocrinol (2002) 1:175–90. 10.2165/00024677-200201030-00005
    1. Vilardaga JP, Romero G, Friedman PA, Gardella TJ. Molecular basis of parathyroid hormone receptor signaling and trafficking: A family B GPCR paradigm. Cell Mol Life Sci (2011) 68:1–13. 10.1007/s00018-010-0465-9
    1. Silva BC, Bilezikian JP. Parathyroid hormone: Anabolic and catabolic actions on the skeleton. Curr Opin Pharmacol (2015) 22:41–50. 10.1016/j.coph.2015.03.005
    1. Kimura S, Yoshioka K. Parathyroid hormone and parathyroid hormone type-1 receptor accelerate myocyte differentiation. Sci Rep (2014) 4:1–8. 10.1038/srep05066
    1. Pioszak AA, Parker NR, Gardella TJ, Xu HE. Structural basis for parathyroid hormone-related protein binding to the parathyroid hormone receptor and design of conformation-selective peptides. J Biol Chem (2009) 284:28382–91. 10.1074/jbc.M109.022905
    1. Hattersley G, Dean T, Corbin BA, Bahar H, Gardella TJ. Binding selectivity of abaloparatide for PTH-type-1-receptor conformations and effects on downstream signaling. Endocrinology (2016) 157:141–9. 10.1210/en.2015-1726
    1. Dean T, Vilardaga JP, Potts JT, Gardella TJ. Altered selectivity of parathyroid hormone (PTH) and PTH-related protein (PTHrP) for distinct conformations of the PTH/PTHrP receptor. Mol Endocrinol (2008) 22:156–66. 10.1210/me.2007-0274
    1. Maeda A, Okazaki M, Baron DM, Dean T, Khatri A, Mahon M, et al. . Critical role of parathyroid hormone (PTH) receptor-1 phosphorylation in regulating acute responses to PTH. Proc Natl Acad Sci USA (2013) 110:5864–9. 10.1073/pnas.1301674110
    1. Miller PD, Hattersley G, Riis BJ, Williams GC, Lau E, Russo LA, et al. . Effect of abaloparatide vs placebo on newvertebral fractures in postmenopausalwomen with osteoporosis a randomized clinical trial. JAMA J Am Med Assoc (2016) 316:722–33. 10.1001/jama.2016.11136
    1. Makino A, Takagi H, Takahashi Y, Hase N, Sugiyama H, Yamana K, et al. . Abaloparatide Exerts Bone Anabolic Effects with Less Stimulation of Bone Resorption-Related Factors: A Comparison with Teriparatide. Calcif Tissue Int (2018) 103:289–97. 10.1007/s00223-018-0422-4
    1. Bernhardsson M, Aspenberg P. Abaloparatide versus teriparatide: a head to head comparison of effects on fracture healing in mouse models. Acta Orthop (2018) 89:674–7. 10.1080/17453674.2018.1523771
    1. Le Henaff C, Ricarte F, Finnie B, He Z, Johnson J, Warshaw J, et al. . Abaloparatide at the Same Dose Has the Same Effects on Bone as PTH (1-34) in Mice. J Bone Miner Res (2020) 35:714–24. 10.1002/jbmr.3930
    1. Brent MB, Brüel A, Thomsen JS. PTH (1–34) and growth hormone in prevention of disuse osteopenia and sarcopenia in rats. Bone (2018) 110:244–53. 10.1016/j.bone.2018.02.017
    1. Brent MB, Thomsen JS, Brüel A. The effect of oral dabigatran etexilate on bone density, strength, and microstructure in healthy mice. Bone Rep (2018) 8:9–17. 10.1016/j.bonr.2017.12.001
    1. Vegger JB, Brüel A, Brent MB, Thomsen JS. Disuse osteopenia induced by botulinum toxin is similar in skeletally mature young and aged female C57BL/6J mice. J Bone Miner Metab (2018) 36:170–9. 10.1007/s00774-017-0830-y
    1. Bouxsein ML, Boyd SK, Christiansen BA, Guldberg RE, Jepsen KJ, Müller R. Guidelines for assessment of bone microstructure in rodents using micro-computed tomography. J Bone Miner Res (2010) 25:1468–86. 10.1002/jbmr.141
    1. Vegger JB, Nielsen ES, Brüel A, Thomsen JS. Additive effect of PTH (1-34) and zoledronate in the prevention of disuse osteopenia in rats. Bone (2014) 66:287–95. 10.1016/j.bone.2014.06.020
    1. Dempster DW, Compston JE, Drezner MK, Glorieux FH, Kanis JA, Malluche H, et al. . Standardized nomenclature, symbols, and units for bone histomorphometry: A 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res (2013) 28:2–17. 10.1002/jbmr.1805
    1. Vegger JB, Brüel A, Dahlgaard AF, Thomsen JS. Alterations in gene expression precede sarcopenia and osteopenia in botulinum toxin immobilized mice. J Musculoskelet Neuronal Interact (2016) 16:355–68.
    1. Varela A, Chouinard L, Lesage E, Guldberg R, Smith SY, Kostenuik PJ, et al. . One year of abaloparatide, a selective peptide activator of the PTH1 receptor, increased bone mass and strength in ovariectomized rats. Bone (2017) 95:143–50. 10.1016/j.bone.2016.11.027
    1. Brent MB, Thomsen JS, Brüel A. The Efficacy of PTH and Abaloparatide to Counteract Immobilization-Induced Osteopenia Is in General Similar. Front Endocrinol (Lausanne) (2020) 11:588773. 10.3389/fendo.2020.588773
    1. Kim SW, Pajevic PD, Selig M, Barry KJ, Yang JY, Shin CS, et al. . Intermittent parathyroid hormone administration converts quiescent lining cells to active osteoblasts. J Bone Miner Res (2012) 27:2075–84. 10.1002/jbmr.1665
    1. Varela A, Chouinard L, Lesage E, Smith SY, Hattersley G. One Year of Abaloparatide, a Selective Activator of the PTH1 Receptor, Increased Bone Formation and Bone Mass in Osteopenic Ovariectomized Rats Without Increasing Bone Resorption. J Bone Miner Res (2017) 32:24–33. 10.1002/jbmr.3003
    1. Doyle N, Varela A, Haile S, Guldberg R, Kostenuik PJ, Ominsky MS, et al. . Abaloparatide, a novel PTH receptor agonist, increased bone mass and strength in ovariectomized cynomolgus monkeys by increasing bone formation without increasing bone resorption. Osteoporos Int (2018) 29:685–97. 10.1007/s00198-017-4323-6
    1. Chandler H, Lanske B, Varela A, Guillot M, Boyer M, Brown J, et al. . Abaloparatide, a novel osteoanabolic PTHrP analog, increases cortical and trabecular bone mass and architecture in orchiectomized rats by increasing bone formation without increasing bone resorption. Bone (2019) 120:148–55. 10.1016/j.bone.2018.10.012
    1. Culler M, Dong J, Shen Y, Taylor J, Carlile L, Sullican T, et al. . BIM-44058, a Novel Analog of PTHrP With Enhanced Bone Building Activity, but Decreased Calcium-Mobilization Potential. J Bone Miner Res (2001) 16:M460.
    1. Makino A, Hasegawa T, Takagi H, Takahashi Y, Hase N, Amizuka N. Frequent administration of abaloparatide shows greater gains in bone anabolic window and bone mineral density in mice: A comparison with teriparatide. Bone (2020) 142:115651. 10.1016/j.bone.2020.115651
    1. Sahbani K, Cardozo CP, Bauman WA, Tawfeek HA. Abaloparatide exhibits greater osteoanabolic response and higher cAMP stimulation and β-arrestin recruitment than teriparatide. Physiol Rep (2019) 7:e14225. 10.14814/phy2.14225
    1. Arlt H, Mullarkey T, Hu D, Baron R, Ominsky MS, Mitlak B, et al. . Effects of abaloparatide and teriparatide on bone resorption and bone formation in female mice. Bone Rep (2020) 13:100291. 10.1016/j.bonr.2020.100291
    1. Brent MB, Lodberg A, Bromer FD, van der Eerden BCJ, Eijken M, Brüel A, et al. . Activin type IIA decoy receptor and intermittent parathyroid hormone in combination overturns the bone loss in disuse-osteopenic mice. Bone (2021) 142:115692. 10.1016/j.bone.2020.115692
    1. Kramer I, Loots GG, Studer A, Keller H, Kneissel M. Parathyroid Hormone (PTH)-induced bone gain is blunted in SOST overexpressing and deficient mice. J Bone Miner Res (2010) 25:178–89. 10.1359/jbmr.090730
    1. Meakin LB, Todd H, Delisser PJ, Galea GL, Moustafa A, Lanyon LE, et al. . Parathyroid hormone’s enhancement of bones’ osteogenic response to loading is affected by ageing in a dose- and time-dependent manner. Bone (2017) 98:59–67. 10.1016/j.bone.2017.02.009

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する